Dickinson Andrew D 4

What Happened Andrew D. Dickinson, Chief Financial Officer of Gilead Sciences (GILD), sold 3,000 shares on February 17, 2026 at $154.43 per share for proceeds of $463,290. The filing lists the transaction as an open-market or private sale (code S), i.e., a disposition of company stock. This was a sale (not a purchase), which is often routine for executives but does reduce insider holdings.

Key Details

• Transaction date and price: 2026-02-17, 3,000 shares at $154.43 each (total $463,290).
• Transaction type: Sale (S) — reported as open market or private sale.
• Shares owned after transaction: Not specified in the excerpt provided; filing notes the balance was adjusted to reflect shares acquired under Gilead’s Employee Stock Purchase Plan (see footnote F2).
• Notable footnotes:
  • F1 — The sale was made pursuant to a Rule 10b5-1 trading plan adopted Aug 29, 2024.
  • F2 — Balance adjusted for shares acquired under the Gilead ESPP.
• Filing timeliness: No late filing was indicated in the provided filing.

Context Sales under a pre-established Rule 10b5-1 plan are typically automated arrangements that allow insiders to sell shares on a schedule and can limit how much the transaction indicates the insider’s current view of the company. For retail investors, purchases generally carry stronger signals than sales; this transaction appears to be a planned disposition rather than an ad‑hoc sale.